Treating lung cancer in patients with interstitial lung disease: what do we know?

Journal of Thoracic Disease

article

Alexander Graur¹  Sydney B. Montesi²  Michael Lanuti³  Florian J. Fintelmann¹ 

[1] Department of Radiology, Division of Thoracic Imaging and Intervention, Massachusetts General Hospital;Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital;Department of Surgery, Division of Thoracic Surgery, Massachusetts General Hospital

关键词: Lung cancer;    cryoablation;    interstitial lung disease;    pulmonary fibrosis;   

DOI  :  10.21037/jtd-23-316

学科分类：呼吸医学

来源: Pioneer Bioscience Publishing Company

【 摘 要 】

Management of interstitial lung disease (ILD) remains a challenge for patients and healthcare providers. While pirfenidone and nintedanib, so termed anti-fibrotic agents, have been shown to slow decline in pulmonary function, decrease all-cause mortality and the rate of acute exacerbations (AE-ILD) in idiopathic pulmonary fibrosis (IPF) (1-4), morbidity and mortality remain high for IPF, the most deadly ILD (5,6). In addition to progressive decline in lung function and AE-ILD, patients with IPF are at risk for pulmonary hypertension, venous thromboembolism, and lung cancer (6-8). Patients with coexistent ILD and lung cancer have a worse survival than patients with lung cancer alone (9).

【 授权许可】

Unknown